Head-to-head · WeighScore
HelloWellness vs Zealthy
The verdict
HelloWellness takes it — 60.9/100 to 46.7/100.
HelloWellness grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HelloWellness (hellowellness.health) is a compounded GLP-1 telehealth platform offering compounded semaglutide starting at $133/month and compounded tirzepatide starting at $166/month, with a 3-month plan…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HelloWellness | Zealthy |
|---|---|---|
| WeighScore | 60.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #310 | #496 |
| Semaglutide | $133/mo (starting dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $166/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #310 · C
Strengths
- $133/mo starting price for compounded semaglutide is among the cheapest in the US compounded market
- $166/mo starting price for compounded tirzepatide is competitive with established platforms
- Every shipment includes syringes, needles, and injection instructions
- Cancel anytime after the 3-month minimum, stated clearly
- Private Facebook community for patient support
Where it loses points
- 3-month minimum plan — you pay for all 3 months even if you stop early
- LegitScript seal is for a related domain (hellowellness.ai), not hellowellness.health — confirm it's the same entity
- Parent company / legal entity not disclosed
- States served not listed publicly
- Pharmacy partners not named
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.